Teijin Limited (hereinafter, 'the Company') hereby announces that it has resolved at its Board of Directors meeting held today that the Company and its subsidiary Teijin Pharma Limited (Head office: Chiyoda-ku, Tokyo; President: Masaki Taneda; hereinafter 'Teijin Pharma') enter into an exclusive licensing agreement with Ascendis Pharma, A/S (Head office: Copenhagen, Denmark; President and CEO: Jan Moller Mikkelsen; hereinafter, 'Ascendis') regarding the research, development, manufacturing and sales in Japan for 'TransCon hGH, 'TransCon PTH,' and 'TransCon CNP,' three drugs currently under development as hormone therapy drugs to be used for the treatment of rare endocrine diseases.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Germany (Heidelberg and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey).

Contact:

Naoki Hamashima

Tel: +81-3-3506-4395

(C) 2023 Electronic News Publishing, source ENP Newswire